Ovid Therapeutics Announces Senior Management Promotions in Preparation for Multiple Data Readouts Expected in 2020
Ovid Therapeutics Inc. (OVID)
Last ovid therapeutics inc. earnings: 3/11 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.ovidrx.com
Company Research
Source: GlobeNewswire
Amit Rakhit, M.D., MBA, Promoted to President Timothy Daly Promoted to Executive Vice President, Finance NEW YORK, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced two senior leadership changes to further build the company’s capabilities as it approaches topline results from the pivotal Phase 3 NEPTUNE trial for OV101 in Angelman syndrome, expected in mid-2020. Ovid’s Chief Medical Officer and Head of Research and Development, Amit Rakhit, M.D., MBA, has been promoted to President, in which role he will oversee several functions including commercial, research and development, regulatory, and manufacturing. Amit will retain his title as Chief Medical Officer. In addition, Timothy Daly has been promoted to Executive Vice President, Finance to oversee the company’s operations, finance and IT. Tim will retain his titl
Show less
Read more
Impact Snapshot
Event Time:
OVID
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OVID alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OVID alerts
High impacting Ovid Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
OVID
News
- We Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business Growth [Yahoo! Finance]Yahoo! Finance
- Ovid Therapeutics: Data Readouts For Rare Epileptic Indications Late 2024 [Seeking Alpha]Seeking Alpha
- Ovid Therapeutics Inc. (NASDAQ: OVID) is now covered by analysts at Wedbush. They set an "outperform" rating and a $8.00 price target on the stock.MarketBeat
- Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare ConferenceGlobeNewswire
OVID
Earnings
- 3/8/24 - Miss
OVID
Sec Filings
- 4/24/24 - Form ARS
- 4/24/24 - Form DEF
- 4/24/24 - Form DEFA14A
- OVID's page on the SEC website